Stryker Co. (NYSE:SYK) Shares Sold by VisionPoint Advisory Group LLC

VisionPoint Advisory Group LLC reduced its position in Stryker Co. (NYSE:SYK) by 6.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 536 shares of the medical technology company’s stock after selling 38 shares during the period. VisionPoint Advisory Group LLC’s holdings in Stryker were worth $192,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Dunhill Financial LLC grew its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the 4th quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $36,000. Activest Wealth Management acquired a new stake in shares of Stryker during the fourth quarter worth approximately $36,000. Finally, Crews Bank & Trust bought a new stake in shares of Stryker in the fourth quarter worth $39,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 1.0 %

Shares of NYSE:SYK opened at $382.59 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $378.07 and its 200 day moving average price is $368.67. The company has a market cap of $145.99 billion, a PE ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. Sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. BTIG Research increased their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Evercore ISI boosted their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $420.68.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.